Table 5

Vaccine efficacy (VE, 95% CI) against cervical intraepithelial neoplasia grade three and invasive cancer (CIN3+) associated with vaccine and/or non-vaccine HPV types in women vaccinated in 2004/2005 with the HPV-16/18 vaccine between ages 16- to 17 years and in an age-aligned control cohort of originally 18- to 19-year-old women passively followed via Finnish Cancer Registry for up to 10 years post vaccination.

End-point (CIN3+)	Vaccine				Control
End-point (CIN3+)	N	Person yrs	n	Rate#	N	Person yrs	n	Rate#	VE	(95% CI)
HPV16	2 465	12 561	3	24	15 627	85 328	26	30	22	−160 to 73
HPV18	2 465	12 561	–	–	15 627	85 328	3	3.5	100	−1500 to 100
HPV16/18	2 465	12 561	3	24	15 627	85 328	28	33	27	−140 to 74
HPVA9	2 465	12 561	3	24	15 627	85 328	43	50	53	−48 to 83
HPVA9*	2 465	12 561	–	–	15 627	85 328	17	20	100	−65 to 100
HPVA9/A7†	2 465	12 561	–	–	15 627	85 328	18	21	100	−55 to 100
HPV31/33/45	2 465	12 561	–	–	15 627	85 328	13	15	100	−120 to 100
All protected HPV types‡	2 465	12 561	3	24	15 627	85 328	41	48	50	−60 to 82
All protected HPV types§	2 465	12 561	–	–	15 627	85 328	13	15	100	−120 to 100
All non-protected HPVs¶	2 465	12 561	–	–	15 627	85 328	6	7.0	100	-480 to 100
All detected HPV types	2 465	12 561	3	24	15 627	85 328	46	54	56	−38 to 84
All detected HPV types**†	2 465	12 561	–	–	15 627	85 328	18	21	100	−55 to 100
Total††	2 465	12 561	3	24	15 627	85 328	50	56	59	−26 to 85
Total all§§	2 465	12 561	4	32	15 627	85 328	79	66	66	8.4 to 88

A9=HPV16/31/33/35/52/58, A7=HPV18/39/45/59/68,
All vaccine protected HPV types: 6/11/16/18/31/33/45/51/74,
All non-vaccine protected HPV types: 34/35/39/40/42/43/44/52/53/54/56/58/59/66,/68/73 and 70
*(excluding co-infections with 16)
†(excluding co-infections with 16/18)
‡HPV6/11/16/18/31/33/45/51/74
§HPV6/11/31/33/45/51/74 (excluding co-infections with 16/18)
¶ HPV34/35/39/40/42/43/44/52/53/54/56/58/59/66/68/70/73 (excluding co-infections with 16/18),
**HPV positive and HPV negative
††original FCR registered CIN3+ diagnoses
§§incidence/100 000 women years